Inactive Instrument

Analyst Reco. Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

UBS Raises Intercept Pharmaceuticals Price Target to $19 From $12, Maintains Neutral Rating	23-09-27	MT
HC Wainwright Downgrades Intercept Pharmaceuticals to Neutral From Buy, Price Target is $19	23-09-27	MT
Canaccord Genuity Downgrades Intercept Pharmaceuticals to Hold From Buy, Trims Price Target to $19 From $20	23-09-27	MT
RBC Raises Price Target on Intercept Pharmaceuticals to $19 From $12 on Deal to Be Bought by Alfasigma; Sector Perform Kept	23-09-27	MT
B. Riley Downgrades Intercept Pharmaceuticals to Neutral From Buy After Announced Sale to Alfasigma, Lifts PT to $19 From $15	23-09-27	MT
UBS Adjusts Intercept Pharmaceuticals Price Target to $12 From $20, Maintains Neutral Rating	23-08-14	MT
HC Wainwright Double Upgrades Intercept Pharmaceuticals to Buy From Sell, Raises Price Target to $19 From $8; Shares up 12% Premarket	23-07-13	MT
Investors aren't fazed by rate hikes anymore	23-06-29
Canaccord Genuity Upgrades Intercept Pharmaceuticals to Buy From Hold	23-06-29	MT
ANALYST RECOMMENDATIONS : Ashtead, Beaze Homes, Hibbett, Micron, Viad...	23-06-29
RBC Trims PT on Intercept Pharmaceuticals to $13 From $14 as Expense Cuts Look 'Less Sharp' Than Firm Expected; Sector Perform Kept	23-06-26	MT
B. Riley Cuts Intercept Pharmaceuticals' PT to $15 From $30, Updates Model After FDA Advisory Panel Denies NASH Accelerated Approval; Keeps Buy Rating	23-05-30	MT
BofA Securities Adjusts Price Target on Intercept Pharmaceuticals to $14 From $17, Keeps Underperform Rating	23-05-23	MT
Needham Downgrades Intercept Pharmaceuticals to Hold From Buy	23-05-23	MT
Baird Lowers Intercept Pharmaceuticals' Price Target to $18 From $35, Maintains Outperform Rating	23-05-22	MT
Goldman Sachs Cuts Intercept Pharmaceuticals' Price Target to $10 From $12, Sell Rating Kept	23-05-22	MT
Canaccord Genuity Cuts Intercept Pharmaceuticals' Price Target to $12 From $26, Maintains Hold Rating	23-05-22	MT
Baird Cuts Price Target on Intercept Pharmaceuticals to $18 From $35, Maintains Outperform Rating	23-05-22	MT
HC Wainwright Downgrades Intercept Pharmaceuticals to Sell From Neutral, Adjusts Price Target to $8 From $14	23-05-22	MT
Raymond James Downgrades Intercept Pharmaceuticals to Market Perform From Outperform	23-05-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Analyst Reco.

Filters